We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$7.99B
AUM Growth
+$1.36B
Cap. Flow
+$167M
Cap. Flow %
2.09%
Top 10 Hldgs %
82.62%
Holding
149
New
30
Increased
33
Reduced
21
Closed
40

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$40.6M
2
TSRO
TESARO, Inc.
TSRO
+$32.2M
3
BPMC
Blueprint Medicines
BPMC
+$30.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$25.8M
5
FOLD
Amicus Therapeutics
FOLD
+$22.8M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$21.1M
2
INCY icon
Incyte
INCY
+$18M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.37M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$5.83M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.72M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.57%
2 Consumer Discretionary 23.48%
3 Healthcare 17.53%
4 Communication Services 0.15%
5 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCRB icon
126
Seres Therapeutics
MCRB
$45M
– –
-15,000
Closed -$3.04M
MET icon
127
CALL
MetLife
MET
$62.4B
– –
-250,000
Closed -$12.6M
MGNX icon
128
MacroGenics
MGNX
$233M
– –
-100,000
Closed -$1.9M
MS icon
129
CALL
Morgan Stanley
MS
$319B
– –
-500,000
Closed -$26.2M
NBIX icon
130
Neurocrine Biosciences
NBIX
$18.2B
– –
-250,000
Closed -$21.1M
PBYI icon
131
Puma Biotechnology
PBYI
$398M
– –
-50,000
Closed -$4.94M
RYTM icon
132
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-50,000
Closed -$1.45M
VALE icon
133
CALL
Vale
VALE
$62.3B
– –
-500,000
Closed -$6.12M
VSTM icon
134
Verastem
VSTM
$528M
– –
-83,333
Closed -$3.07M
ZTO icon
135
CALL
ZTO Express
ZTO
$18.2B
– –
-500,000
Closed -$7.92M
LUMO
136
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-22,222
Closed -$1.62M
MRTX
137
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$1.82M
JNCE
138
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-150,000
Closed -$1.91M
CLVS
139
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-100,000
Closed -$5.83M
CCXI
140
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-500,000
Closed -$2.98M
RDUS
141
CALL
DELISTED
Radius Health, Inc.
RDUS
– –
-100,000
Closed -$3.18M
CALA
142
DELISTED
Calithera Biosciences, Inc
CALA
– –
-5,000
Closed -$835K
AGN
143
CALL
DELISTED
Allergan plc
AGN
– –
-200,000
Closed -$32.7M
ALDR
144
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-500,000
Closed -$5.72M
ARRY
145
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-500,000
Closed -$6.4M
HZNP
146
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-500,000
Closed -$7.3M
AKAO
147
DELISTED
Achaogen Inc
AKAO
– –
-250,000
Closed -$2.69M
JUNO
148
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-350,000
Closed -$16M
JUNO
149
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-100,000
Closed -$4.57M
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2018 Portfolio in Review

As of Q1 2018, Artal Group held 149 positions worth $7.99B, up 21% from $6.63B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2018 filing shows 30 new, 33 increased, 21 reduced and 40 closed positions. Its largest new stake was Kyntra Bio: 10,000 shares worth $11.6M. The largest sale was Neurocrine Biosciences, an estimated $21.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2018 buy was Kyntra Bio: 10,000 shares worth $11.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q1 2018, an estimated $40.6M increase.
  • Artal Group's biggest Q1 2018 reduction was Incyte, cutting an estimated $18M.
  • Artal Group fully exited Neurocrine Biosciences in Q1 2018, selling an estimated $21.1M.
  • Artal Group's ten largest holdings make up 83% of its $7.99B portfolio in Q1 2018.
  • Artal Group opened 30 new positions and closed 40 in Q1 2018.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $7.99B.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.